Antineoplastic chemotherapy in Jehovah's Witness patients with acute myelogenous leukemia refusing blood products – a matched pair analysis

References

• Atallah E, Cortes J, O’Brien S, et al. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007;110(10):3547–3551. DOI: 10.1182/blood-2007-06-095844. PubMed PMID: 17673605.
   PubMed Web of Science ®Google Scholar
• About Jehovah’s Witnesses, Internet. [cited 2016 Nov 28]. Available from: https://www.jw.org/en/jehovahs-witnesses/
   Google Scholar
• Marsh JC, Bevan DH. Haematological care of the Jehovah’s Witness patient. Br J Haematol. 2002;119(1):25–37. PubMed PMID: 12358900. doi: 10.1046/j.1365-2141.2002.03639.x
   PubMed Web of Science ®Google Scholar
• Lawson T, Ralph C. Perioperative Jehovah’s Witnesses: a review. Br J Anaesth. 2015;115(5):676–687. DOI: 10.1093/bja/aev161. PubMed PMID: 26068896.
   PubMed Web of Science ®Google Scholar
• Brown NM, Keck G, Ford PA. Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma. 2008;49(4):817–820. DOI: 10.1080/10428190801911670. PubMed PMID: 18398752.
   PubMed Web of Science ®Google Scholar
• Cardenas-Araujo D, Gonzalez-Lopez EE, Gonzalez-Leal XJ, et al. A clinical challenge: treatment of acute myeloid leukemia in a Jehovah’s Witness. Revista brasileira de hematologia e hemoterapia. 2016;38(4):358–360. DOI: 10.1016/j.bjhh.2016.05.003. PubMed PMID: 27863765; PubMed Central PMCID: PMC5119660.
   PubMedGoogle Scholar
• Dalal S, Boddapati M, Lowery MN, et al. Treatment of acute myeloid leukemia in a Jehovah’s Witness. Ann Hematol. 2006;85(6):407–408. DOI: 10.1007/s00277-006-0087-3. PubMed PMID: 16518601.
   PubMed Web of Science ®Google Scholar
• Garelius H, Grund S, Stockelberg D. Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah’s Witness with acute monocytic leukemia. Clin Case Rep. 2015;3(5):287–290. DOI: 10.1002/ccr3.212. PubMed PMID: 25984306; PubMed Central PMCID: PMC4427369.
   PubMed Web of Science ®Google Scholar
• McEwan I. The Children Act. London: Nan A. Talese; 2014.
   Google Scholar
• Broccia G. Long-term continuous complete remission of acute myeloid leukemia in a Jehovah’s Witness treated without blood support. Haematologica. 1994;79(2):180–181. PubMed PMID: 8063269.
   PubMed Web of Science ®Google Scholar
• Cullis JO, Duncombe AS, Dudley JM, et al. Acute leukaemia in Jehovah’s Witnesses. Br J Haematol. 1998;100(4):664–668. PubMed PMID: 9531331. doi: 10.1046/j.1365-2141.1998.00634.x
   PubMed Web of Science ®Google Scholar
• Menendez A, Svarch E, Martinez G, et al. Successful treatment of acute promyelocytic leukemia using all-trans retinoic acid and erythropoietin in a Jehovah’s Witness boy. Ann Hematol. 1998;76(1):43–44. PubMed PMID: 9486924. doi: 10.1007/s002770050359
   PubMed Web of Science ®Google Scholar
• Keane C, Mollee P, Marlton P, et al. Treatment of acute promyelocytic leukaemia in the Jehovah’s Witness population. Ann Hematol. 2011;90(3):359–360. DOI: 10.1007/s00277-010-1023-0. PubMed PMID: 20607537.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31(2):272–281. DOI: 10.1038/leu.2016.275. PubMed PMID: 27721426.
   PubMed Web of Science ®Google Scholar
• Hospital MA, Green AS, Maciel TT, et al. FLT3 inhibitors: clinical potential in acute myeloid leukemia. OncoTargets Ther. 2017;10:607–615. DOI: 10.2147/OTT.S103790. PubMed PMID: 28223820; PubMed Central PMCID: PMC5304990.
   PubMed Web of Science ®Google Scholar
• Ford PA, Grant SJ, Mick R, et al. Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah’s witnesses. J Clin Oncol. 2015;33(15):1674–1679. DOI: 10.1200/JCO.2014.57.9912. PubMed PMID: 25870085; PubMed Central PMCID: PMC4559609.
   PubMed Web of Science ®Google Scholar
• Al-Nawakil C, Quarre MC, Heshmati F, et al. Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. Br J Haematol. 2013;161(5):738–740. DOI: 10.1111/bjh.12284. PubMed PMID: 23480574.
   PubMed Web of Science ®Google Scholar
• Sloan JM, Ballen K. SCT in Jehovah’s Witnesses: the bloodless transplant. Bone Marrow Transplant. 2008;41(10):837–844. DOI: 10.1038/bmt.2008.5. PubMed PMID: 18246110.
   PubMed Web of Science ®Google Scholar
• Carson JL, Noveck H, Berlin JA, et al. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion. 2002;42(7):812–818. PubMed PMID: 12375651. doi: 10.1046/j.1537-2995.2002.00123.x
   PubMed Web of Science ®Google Scholar
• Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406–3417. PubMed PMID: 19188662. doi: 10.1182/blood-2008-10-167643
   PubMed Web of Science ®Google Scholar
• Heh-Foster AM, Naber M, Pai MP, et al. Epoetin in the ‘untransfusable’ anaemic patient: a retrospective case series and systematic analysis of literature case reports. Transfus Med. 2014;24(4):204–208. DOI: 10.1111/tme.12120. PubMed PMID: 24697987.
   PubMed Web of Science ®Google Scholar
• Oberhoff C. Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins. Support Care Cancer. 2007;15(6):603–611. PubMed PMID: 17277926. doi: 10.1007/s00520-006-0191-x
   PubMed Web of Science ®Google Scholar
• Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10):965–976. PubMed PMID: 17804841. doi: 10.1056/NEJMoa071533
   PubMed Web of Science ®Google Scholar
• Michallet M, Goldet K, Sobh M, et al. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer. 2013;119(1):107–114. DOI: 10.1002/cncr.27686. PubMed PMID: 22744794.
   PubMed Web of Science ®Google Scholar
• Allison G, Feeney C. Successful use of a polymerized hemoglobin blood substitute in a critically anemic Jehovah’s Witness. South Med J. 2004;97(12):1257–1258. PubMed PMID: 15646766. doi: 10.1097/01.SMJ.0000140857.11967.2D
   PubMed Web of Science ®Google Scholar
• Torres Filho IP, Spiess BD, Barbee RW, et al. Systemic responses to hemodilution after transfusion with stored blood and with a hemoglobin-based oxygen carrier. Anesth Analg. 2005;100(4):912–920. PubMed PMID: 15781498. doi: 10.1213/01.ANE.0000146960.79532.DB
   PubMed Web of Science ®Google Scholar
• Marelli TR. Use of a hemoglobin substitute in the anemic Jehovah’s Witness patient. Crit Care Nurse. 1994;14(1):31–38. PubMed PMID: 8194324.
   PubMedGoogle Scholar
• Lanzinger MJ, Niklason LE, Shannon M, et al. Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah’s Witness. Can J Anaesth. 2005;52(4):369–373. PubMed PMID: 15814750. doi: 10.1007/BF03016278
   PubMed Web of Science ®Google Scholar
• Smith SE, Toor A, Rodriguez T, et al. The administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah’s Witness after submyeloablative stem cell transplantation complicated by delayed graft failure. Compr Ther. 2006;32(3):172–175. PubMed PMID: 17435270. doi: 10.1007/s12019-006-0008-3
   PubMedGoogle Scholar
• Estcourt LJ, Desborough M, Hopewell S, et al. Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia. Cochrane Database Syst Rev. 2015;2015(6). DOI: 10.1002/14651858.CD011771. PubMed PMID: 26814707; PubMed Central PMCID: PMC4699253.
   Google Scholar
• Muramoto O. Bioethics of the refusal of blood by Jehovah’s Witnesses: Part 2. A novel approach based on rational non-interventional paternalism. J Med Ethics. 1998;24(5):295–301. PubMed PMID: 9800583; PubMed Central PMCID: PMC1377601. doi: 10.1136/jme.24.5.295
   PubMed Web of Science ®Google Scholar
• Muramoto O. Bioethics of the refusal of blood by Jehovah’s Witnesses: Part 1. Should bioethical deliberation consider dissidents’ views?. J Med Ethics. 1998;24(4):223–230. PubMed PMID: 9752623; PubMed Central PMCID: PMC1377670. doi: 10.1136/jme.24.4.223
   PubMed Web of Science ®Google Scholar
• Muramoto O. Bioethics of the refusal of blood by Jehovah’s Witnesses: Part 3. A proposal for a don’t-ask-don’t-tell policy. J Med Ethics. 1999;25(6):463–468. PubMed PMID: 10635499; PubMed Central PMCID: PMC479294. doi: 10.1136/jme.25.6.463
   PubMed Web of Science ®Google Scholar
• Rajtar M. Bioethics and religious bodies: refusal of blood transfusions in Germany. Soc Sci Med. 2013;98:271–277. DOI: 10.1016/j.socscimed.2013.02.043. PubMed PMID: 23538204.
   PubMed Web of Science ®Google Scholar